ko	pathway	ratio_in_study	ratio_in_pop	p_value
ko05160	Hepatitis C	2/3	153/7206	0.00132500196212
ko05205	Proteoglycans in cancer	2/3	271/7206	0.00412266535485
ko05219	Bladder cancer	1/3	48/7206	0.0198532683425
ko05213	Endometrial cancer	1/3	62/7206	0.0255938984297
ko05221	Acute myeloid leukemia	1/3	63/7206	0.0260030835227
ko05223	Non-small cell lung cancer	1/3	66/7206	0.0272299514488
ko04730	Long-term depression	1/3	78/7206	0.0321271205573
ko05214	Glioma	1/3	79/7206	0.032534474463
ko05212	Pancreatic cancer	1/3	83/7206	0.0341627471169
ko05220	Chronic myeloid leukemia	1/3	85/7206	0.0349761978874
ko05218	Melanoma	1/3	85/7206	0.0349761978874
ko05210	Colorectal cancer	1/3	86/7206	0.0353827519394
ko05211	Renal cell carcinoma	1/3	96/7206	0.0394420140777
ko04650	Natural killer cell mediated cytotoxicity	1/3	97/7206	0.0398473128057
ko04720	Long-term potentiation	1/3	99/7206	0.0406575682064
ko04914	Progesterone-mediated oocyte maturation	1/3	104/7206	0.0426812121268
ko01521	EGFR tyrosine kinase inhibitor resistance	1/3	106/7206	0.0434898721995
ko04012	ErbB signaling pathway	1/3	109/7206	0.0447020082512
ko05215	Prostate cancer	1/3	111/7206	0.0455095297678